Kringle Pharma Overview

  • Founded
  • 2001
Founded
  • Status
  • Public
  • Employees
  • 10
Employees
  • Stock Symbol
  • 4884
Stock Symbol
  • Share Price
  • $6.36
  • (As of Wednesday Closing)

Kringle Pharma General Information

Description

Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
TKS
Primary Office
  • 207 Saito Bio-Incubator
  • 7-7-15 Saitoasagi, Ibaraki
  • Osaka, 567-0085
  • Japan
+81 000-000-0000

Kringle Pharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kringle Pharma Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.36 $6.56 $6.19 - $17.19 $27.5M 4.32M 23.5K $1.23

Kringle Pharma Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 30-Sep-2020 FY 2019 30-Sep-2019 FY 2018 30-Sep-2018
EV 22,015
Revenue 4,918 4,336 0
EBITDA (2,741) (581)
Net Income (1,849) (1,093) (2,745) (584)
Total Assets 23,695 22,241 2,333 4,986
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kringle Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kringle Pharma‘s full profile, request access.

Request a free trial

Kringle Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic
Drug Discovery
Osaka, Japan
10 As of 2020
000.00
00.00 0000-00-00
00000000 000.00

000 0000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000 000000000
Barcelona, Spain
00 As of 0000
0000
00000000000 0000

00000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, q
0000 000000000
New York, NY
00 As of 0000
0000
00.00 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kringle Pharma Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
00000000 Venture Capital-Backed New York, NY 00 0000 00000000000 0000
00 000000000000 Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
0000000 000000 Venture Capital-Backed Stockholm, Sweden 0 000.00 0000000000 0 000.00
You’re viewing 5 of 10 competitors. Get the full list »

Kringle Pharma Patents

Kringle Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2018044000-A Hgf formulations suitable for treatment of neurological diseases Pending 10-Sep-2014 00000000000
US-20170333527-A1 Hgf preparation suitable for treatment of neurological disorders Granted 10-Sep-2014 00000000000 0
US-20190117732-A1 Hgf preparation suitable for treatment of neurological disorders Granted 10-Sep-2014 00000000000
JP-WO2016039163-A1 Hgf preparation suitable for treatment of neurological diseases Granted 10-Sep-2014 00000000000
US-10213485-B2 Hgf preparation suitable for treatment of neurological disorders Active 10-Sep-2014 A61K38/1833 0

Kringle Pharma Executive Team (3)

Name Title Board Seat Contact Info
Kiichi Adachi Ph.D President, Chief Executive Officer & Board Member
Kunio Matsumoto Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

Kringle Pharma Board Members (10)

Name Representing Role Since
Akihiro Tomoyasu Ph.D Self Board Member 000 0000
Etsuro Hashimura Kringle Pharma Board Member 000 0000
Hiroshi Ishiai Ph.D Kringle Pharma Board Member 000 0000
Hiroshi Matsuura Self Board Member 000 0000
Hisashi Mitsuguchi DBJ Capital Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Kringle Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kringle Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kringle Pharma‘s full profile, request access.

Request a free trial